Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has been assigned a consensus recommendation of “Hold” from the twenty-five ratings firms that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $130.88.
Several equities analysts have weighed in on the company. Seaport Global Securities restated a “buy” rating and set a $136.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, October 6th. JMP Securities restated an “outperform” rating and set a $140.00 target price (down from $150.00) on shares of Intercept Pharmaceuticals in a report on Tuesday, September 26th. Jefferies Group restated a “buy” rating and set a $275.00 target price on shares of Intercept Pharmaceuticals in a report on Wednesday, September 20th. BidaskClub lowered Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Finally, Citigroup set a $74.00 target price on Intercept Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, December 21st.
Shares of Intercept Pharmaceuticals (NASDAQ ICPT) opened at $54.95 on Monday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals has a 1-year low of $52.11 and a 1-year high of $135.59. The stock has a market capitalization of $1,379.36, a price-to-earnings ratio of -3.71 and a beta of -2.05.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The business had revenue of $41.33 million during the quarter, compared to analyst estimates of $36.95 million. During the same period last year, the company earned ($3.59) earnings per share. Intercept Pharmaceuticals’s quarterly revenue was up 697.9% compared to the same quarter last year. analysts predict that Intercept Pharmaceuticals will post -13.36 EPS for the current year.
Several large investors have recently modified their holdings of the company. GSA Capital Partners LLP acquired a new stake in shares of Intercept Pharmaceuticals in the third quarter valued at about $731,000. Ladenburg Thalmann Financial Services Inc. grew its position in shares of Intercept Pharmaceuticals by 292.0% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,582 shares of the biopharmaceutical company’s stock valued at $440,000 after purchasing an additional 5,648 shares during the last quarter. Cubist Systematic Strategies LLC grew its position in shares of Intercept Pharmaceuticals by 68.6% in the third quarter. Cubist Systematic Strategies LLC now owns 6,717 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 2,734 shares during the last quarter. Cowen Inc. acquired a new stake in shares of Intercept Pharmaceuticals in the third quarter valued at about $1,161,000. Finally, Royce & Associates LP acquired a new stake in shares of Intercept Pharmaceuticals in the third quarter valued at about $1,567,000. 73.76% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This report was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/15/intercept-pharmaceuticals-inc-icpt-given-consensus-recommendation-of-hold-by-brokerages.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.